<DOC>
	<DOCNO>NCT01310231</DOCNO>
	<brief_summary>The purpose study determine addition metformin standard chemotherapy improve progression free survival woman metastatic breast cancer .</brief_summary>
	<brief_title>A Trial Standard Chemotherapy With Metformin ( v Placebo ) Women With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<criteria>Histologically proven invasive breast cancer metastatic spread outside breast , ipsilateral axillary supraclavicular nodal area ( Histological confirmation metastasis require ) OR , Locally advance breast cancer refractory initial anticancer treatment . A decision make administer single multiple agent first second line chemotherapy include one follow agent : anthracycline , taxane , platinum , capecitabine . Age : 18 75 year time registration Invasive breast cancer , ER PgR status ECOG performance status 02 Life expectancy least 6 month Adequate hepatic renal function ( SGOT ALT &lt; 1.8 X upper limit normal institution , alkaline phosphatase ≤ 2X upper limit normal institution , bilirubin within normal limit institution ( expect patient Gilbert 's syndrome eligible regardless bilirubin ) creatinine ≤ 130 umol/L ) Blood count : Neutrophils must least 1,000/mm3 Platelets ≥ 75,000/mm3 . Ability understand provide write informed consent study Absence psychological , familial , sociological , patient related factor might preclude compliance study protocol Measurable non measurable ( evaluable ) tumour must present radiologic clinical evaluation must perform within 4 week prior registration . More one previous line ( ) chemotherapy metastatic disease prior chemotherapy administer , last date treatment must give least 3 week prior registration [ adjuvant systemic treatment acceptable ] If prior hormone therapy ( adjuvant metastatic therapy ) administer , must stop least 3 week prior registration Radiotherapy target non target lesion within 4 week registration Known CNS metastases History cardiac failure Known hypersensitivity allergy metformin History know diabetes baseline fast glucose ≥ 7.0 mmol/L History lactic metabolic acidosis Use metformin within 3 month registration Current plan pregnancy lactation woman childbearing potential . Patients childbearing potential must negative serum pregnancy test . Fertile patient must agree use effective method contraception study treatment ; could include IUD , condom barrier method birth control Habitual alcohol intake three drink daily Concurrent use biguanide medication ( metformin study medication ) Patients ≥ grade 2 diarrhea baseline , malabsorption syndrome unable swallow oral medication Previous concurrent malignancy , except nonmelanoma skin cancer , unless curatively treat evidence recurrence ≥ 5 year . Use investigational agent within 28 day prior registration .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>Metformin</keyword>
</DOC>